Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy

Varun Kumar(Alnylam Pharmaceuticals (United States)), June Qin(Alnylam Pharmaceuticals (United States)), Yongfeng Jiang(Alnylam Pharmaceuticals (United States)), Richard G. Duncan(Alnylam Pharmaceuticals (United States)), Benjamin Brigham(Alnylam Pharmaceuticals (United States)), Shannon Fishman(Alnylam Pharmaceuticals (United States)), Jayaprakash K. Nair(Alnylam Pharmaceuticals (United States)), Akin Akinc(Alnylam Pharmaceuticals (United States)), Scott Barros(Alnylam Pharmaceuticals (United States)), Pia V. Kasperkovitz(Alnylam Pharmaceuticals (United States))
Molecular Therapy — Nucleic Acids
January 1, 2014
Cited by 214Open Access
Full Text

Abstract

Formulation of short interfering RNA (siRNA) into multicomponent lipid nanoparticles (LNP) is an effective strategy for hepatic delivery and therapeutic gene silencing. This study systematically evaluated the effect of polyethylene glycol (PEG) density on LNP physicochemical properties, innate immune response stimulation, and in vivo efficacy. Increased PEG density not only shielded LNP surface charge but also reduced hemolytic activity, suggesting the formation of a steric barrier. In addition, increasing the PEG density reduced LNP immunostimulatory potential as reflected in cytokine induction both in vivo and in vitro. Higher PEG density also hindered in vivo efficacy, presumably due to reduced association with apolipoprotein E (ApoE), a protein which serves as an endogenous targeting ligand to hepatocytes. This effect could be overcome by incorporating an exogenous targeting ligand into the highly shielded LNPs, thereby circumventing the requirement for ApoE association. Therefore, these studies provide useful information for the rational design of LNP-based siRNA delivery systems with an optimal safety and efficacy profile.


Related Papers

No related papers found

Powered by citation graph analysis